Seres Therapeutics grants 6,500 stock options to director

Seres Therapeutics, Inc. reported that director Robert L. Rosiello received a grant of stock options covering 6,500 shares of common stock at an exercise price of $7.14 per share.

Rhea-AI Filing Summary

Seres Therapeutics, Inc. reported that director Robert L. Rosiello received a grant of stock options covering 6,500 shares of common stock at an exercise price of $7.14 per share. These options vest and become exercisable on the earlier of July 8, 2027 or the day immediately before the first annual stockholder meeting occurring after July 8, 2026, and expire on July 7, 2036. Following this grant, Rosiello holds 6,500 derivative securities directly.

Insider Trade Summary

Grant/Award: 6,500 shares

Grant/Award 1 txn

Insider Rosiello Robert L.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy) F1	6,500	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 6,500 contracts (Direct)

Footnotes (1)

1. F1. The option vests and becomes exercisable on the earlier to occur of (i) July 8, 2027 or (ii) the day immediately prior to the first annual meeting of the Company's stockholders occurring after July 8, 2026.

Key Figures

Option Shares Granted: 6,500 shares Exercise Price: $7.14 per share Underlying Shares: 6,500 shares +3 more

6 metrics

Option Shares Granted 6,500 shares Stock options granted to director Robert L. Rosiello

Exercise Price $7.14 per share Exercise price of the granted stock options

Underlying Shares 6,500 shares Common stock underlying the granted stock options

Post-Grant Derivative Holdings 6,500 derivative securities Total options held directly after the transaction

Vesting Date Trigger July 8, 2027 Latest vesting date, or earlier if specified stockholder meeting occurs

Expiration Date July 7, 2036 Expiration of the granted stock options

Key Terms

Stock Option, exercise price, vests and becomes exercisable, annual meeting of the Company's stockholders

4 terms

Stock Option financial

"security_title: "Stock Option (right to buy)""

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

exercise price financial

"conversion_or_exercise_price: "7.1400""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vests and becomes exercisable financial

"The option vests and becomes exercisable on the earlier to occur of"

annual meeting of the Company's stockholders financial

"the first annual meeting of the Company's stockholders occurring after July 8, 2026"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Seres Therapeutics (MCRB) disclose about Robert L. Rosiello in this Form 4?

Seres Therapeutics disclosed that director Robert L. Rosiello received a grant of stock options for 6,500 shares of common stock at an exercise price of $7.14 per share, expiring on July 7, 2036.

How many Seres Therapeutics (MCRB) options did Robert L. Rosiello receive and at what price?

Robert L. Rosiello received stock options for 6,500 shares of Seres Therapeutics common stock with an exercise price of $7.14 per share, according to the Form 4 filing.

When do Robert L. Rosiello’s Seres Therapeutics (MCRB) options vest?

The options vest on the earlier of July 8, 2027 or the day immediately prior to the first annual stockholder meeting occurring after July 8, 2026, as described in the footnote.

What is the expiration date of Robert L. Rosiello’s Seres Therapeutics (MCRB) stock options?

The granted stock options expire on July 7, 2036. After vesting, Rosiello may exercise them at $7.14 per share any time before this expiration date, subject to plan terms.

How many derivative securities does Robert L. Rosiello hold in Seres Therapeutics (MCRB) after this grant?

Following this grant, Robert L. Rosiello holds 6,500 derivative securities (stock options) directly, each relating to one share of Seres Therapeutics common stock, per the Form 4 data.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/10/2026 - 04:15 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rosiello Robert L.

(Last) (First) (Middle)

C/O SERES THERAPEUTICS, INC.

101 CAMBRIDGE PARK DRIVE

(Street)

CAMBRIDGE MASSACHUSETTS 02140

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Seres Therapeutics, Inc. [ MCRB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$7.14	07/08/2026		A		6,500		(1)	07/07/2036	Common Stock	6,500	$0	6,500	D

Explanation of Responses:

1. The option vests and becomes exercisable on the earlier to occur of (i) July 8, 2027 or (ii) the day immediately prior to the first annual meeting of the Company's stockholders occurring after July 8, 2026.

	/s/ Thomas J. DesRosier, Attorney-in-Fact	07/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)